Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease

Launched by AHMADU BELLO UNIVERSITY TEACHING HOSPITAL · Mar 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a treatment called Stellate Ganglion Block might help people who have Cerebral Small Vessel Disease, which can cause problems with swallowing and thinking. The study will include adults over 18 who have been diagnosed with this condition, have difficulty swallowing confirmed by a specific test, and show signs of cognitive impairment (like memory issues). Participants cannot have a history of stroke or other conditions that could affect their swallowing or thinking.

In the trial, participants will be split into two groups. Everyone will receive standard treatments for their condition, but one group will also receive the Stellate Ganglion Block treatment. Researchers will evaluate how well each group performs in terms of swallowing, thinking, and daily activities both before and after the treatment. It’s important to note that the study is not yet recruiting participants, and those interested should check that they meet the eligibility criteria before considering participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\>18 years.
• • Meeting the diagnostic criteria for cerebral small vessel disease.
• • Dysphagia confirmed by Videofluoroscopic Swallowing Study
• • Mini-Mental State Examination (MMSE)\<27, indicating the existence of cognitive impairment.
• • No history of prior stroke.
• Exclusion Criteria:
• • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
• • Cognitive impairment that might be caused by other diseases, such as Alzheimer's disease.
• • Neurological blockade contraindications such as bleeding tendency, blocked site infection.
• • Unable to successfully finish the assessment of this study.
• • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
• • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
• • Pregnant or nursing females